9/27/04

PW

SEP 2 L ZOOM WEEN

PTO/SB/21 (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission

Application Number	10/792,001
Filing Date	3/3/2004
First Named Inventor	Joshua D. Rabinowitz
Art Unit	Not yet known
Examiner Name	To be assigned
Attorney Docket Number	00010.05CON

	ENCLOSURES (check all that apply	)				
Fee Transmittal Form	Drawing(s)	After Allowance communication to Group				
Fee Attached	Licensing-related Papers	Appeal Communication to Board of Appeals and Interferences				
Amendment / Reply	Petition	Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)				
After Final	Petition to Convert a Provisional Application	Proprietary Information				
Affidavits/declaration(s)	Power of Attorney, Revocation Change of Correspondence	Status Letter				
Extension of Time Request	Terminal Disclaimer .	Other Enclosure(s) (please identify below):				
Express Abandonment Request	Request for Refund					
Information Disclosure Statement	CD, Number of CD(s)					
Certified Copy of Priority Document(s)	Remarks	<u> </u>				
Response to Missing Parts/	Lefe Dieal Statement (2 cm)					
Incomplete Application	Info. Discl. Statement (2 pp.) Form 1449 (3 copies, 8 pages each)					
Response to Missing Parts under 37 CFR 1.52 or 1.53	Copy of references / 72 Return postcard					
SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT						
Firm or Individual name  ALEXZA MDC, 1001 East Meadow Circle, Palo Alto, CA 94303  Elaine C Stracker, Ph.D., J.D. Telephone (650)-687-3905  Customer Number 37485						
Signature Signature	( Late					
Date SEP. 2	4 2004					

CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the

Typed or printed name

Elaine C. Stracker

Signature

Date

SEP. 2 4 2004

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Petent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

**CERTIFICATE OF MAILING** 

I HEREBY CERTIFY THAT THIS PAPER AND THE DOCUMENTS REFERRED AS BEING ATTACHED OR ENCLOSED HEREWITH ARE BEING DEPOSITED WITH THE UNITED STATES POSTAL OFFICE ON AS EXPRESS MAIL ADDRESSED TO: MAIL STOP AMENDMENT COMMISSIONER FOR

PATENTS PO BOX 1450 ALEXANDRIA, VA 22313-1450

Elaine C. Stracker

OIL B SCIENT

**PATENT** 

Attorney's Docket No.: 00010.05CON

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:

Rabinowitz et al.

Serial No.:

10/792,001

Filed:

3/3/2004

Title

DELIVERY OF DIAZEPAM THROUGH AN INHALATION ROUTE

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

### INFORMATION DISCLOSURE STATEMENT

#### Dear Sir:

In accordance with their continuing duty of disclosure under 37 CFR §§ §1.97, 1.98 and 1.56, Applicants hereby submit for consideration in the above-identified application the enclosed references. The Information Disclosure statement submitted herewith is being filed within three months of the filing of a national application other than a continued prosecution application under 37 CFR 1.53(d); within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application; before the mailing of a first Office Action on the merits, or before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

For the convenience of the Examiner, the references are listed on a PTO Form 1449 (attached) and copies thereof are enclosed. Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines than an extension and/or other relief is required, Applicants petition for any required relief including any extensions of time and authorizes the Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 502731**. Please direct all correspondence to the following customer number.

Respectfully submitted,

	SEP.	2	4	2004	

Elaine C. Stracker J.D., Ph.D., Reg. 43,166

Alexza Molecular Delivery Corporation 1001 East Meadow Circle Palo Alto, CA 94303

TEL: (650) 687-3905 FAX: (650) 687-3999

Form PTO-1449	Docket Number:	00010.05CON	Application Number: 10/792,001
OINFORMATION DISCLOSURE CITATION IN AN APPLICATION	Applicant:	Rabinowitz et al.	
SEP 2 4 2004 (Use several sheets if necessary)	Filing Date:	03/03/2004	Group Art Unit: Not Yet Known
PRADEMARY			

# U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date ·	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	02/02/1971	3,560,607	Hartley et A.			
	2.	05/27/1980	Re. 30,285	Babington			
	3.	10/21/1980	4,229,447	Porter			
	4.	09/05/1989	4,863,720	Burghart et al.			
	5.	01/23/1990	4,895,719	Radhakrishnun et al.			
	6.	09/17/1991	5,049,389	Radhakrishnun			
	7.	03/31/1992	5,099,861	Clearman et al.			
	8.	02/14/1995	5,388,574	Ingebrethsen			
	9.	10/10/1995	5,457,100	Daniel		,	
	10.	08/06/1996	5,543,434	Weg			
	11.	08/13/1996	5,544,646	5,544,646 Lloyd et al.			
	12.	08/12/1997	5,655,523	Hodson et al.			
	13.	12/09/1997	5,694,919	Rubsamen et al.		-	
	14.	04/07/1998	5,735,263	Rubsamen et al.			
	15.	04/14/1998	5,738,865	Baichwal et al.			
	16.	06/02/1998	5,758,637	Ivri et al.	·		
	17.	06/16/1998	5,767,117	Moskowitz			
-	18.	06/29/1999	5,915,378	Lloyd et al.			
	19.	08/10/1999	5,934,272	Lloyd et al.			
	20.	09/28/1999	5,957,124	Lloyd et al.			
	21.	10/05/1999	5,960,792	Lloyd et al.			
	22.	11/16/1999	5,985,309	Edwards et al.			
	23.	11/30/1999	5,993,805	Sutton et al.			
	24.	03/28/2000	6,041,777	Faithfull et al.			
	25.	04/11/2000	6,048,857	Ellinwood, Jr. et al.			

EXAMINER: DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/ 08 (2-92)

Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PTO/SB/08 (2-92) Sheet 2 of 8

orm PTO-1449	)		Docket Number: 00010.05CON	Application Number: 10/792,001		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Rabinowitz et al.				
	Use several sheets if ned		Filing Date: 03/03/2004	Group Art Unit: Not Yet Known		
26.	04/18/2000	6,051,566	Bianco			
27.	06/20/2000	Re. 36,744	Goldberg			
28.	08/01/2000	6,095,153	Kessler et al.			
29.	08/15/2000	6,102,036	Slutsky et al.			
30.	10/31/2000	6,140,323	Ellinwood, Jr. et al.			
31.	06/05/2001	6,241,969	Saidi et al.			
32.	07/03/2001	6,255,334	Sands			
33.	01/14/2003	6,506,762	Horvath et al.			
34.	07/15/2003	6,591,839	Meyer et al.			
35.	09/06/2001	US 2001/0020147	Staniforth et al.			
36.	03/28/2002	US 2002/0037828	Wilson et al.			
37.	05/16/2002	US 2002/0058009	Bartus et al.			
38.	07/04/2002	US 2002/0086852	Cantor			
39.	08/22/2002	US 2002/0112723	Schuster et al.			
40.	11/28/2002	US 2002/0176841	Barker et al.			
41.	01/02/2003	US 2003/0004142	Prior et al.			
42.	02/13/2003	US 2003/0032638	Kim et al.			
RELAT	ED ALEXZA M	MOLECULAR DELIN	ERY CORPORATION PAT	ENT DOCUMENTS		
43.	08/04/2003	10/633,876	Hale et al.			
44.	08/04/2003	10/633,877	Hale et al.			
45.	12/30/2003	10/749,537	Rabinowitz et al.			
46.	12/30/2003	10/749,539	Rabinowitz et al.			
47.	01/27/2004	10/766,149	Rabinowitz et al.			
· 48.	01/27/2004	10/766,279	Rabinowitz et al.			
49.	01/27/2004	10/766,566	Rabinowitz et al.			
50.	01/27/2004	10/766,574	Rabinowitz et al.			
51.	01/27/2004	10/766,634	Rabinowitz et al.			
52.	01/27/2004	10/766,647	Rabinowitz et al.			
53.	01/28/2004	10/767,115	Rabinowitz et al.			
EXAMINER:			DATE CONSIDERED:			

Form PTO-1449	)		Docket Number: 00010.05CON Application Number: 10/792,001
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant: Rabinowitz et al.
	(Use several sheets if nec		Filing Date: 03/03/2004 Group Art Unit: Not Yet Known
54.	01/29/2004	10/768,205	Rabinowitz et al.
55.	01/29/2004	10/768,220	Rabinowitz et al.
56.	01/29/2004	10/768,281	Rabinowitz et al.
57.	01/29/2004	10/768,293	Rabinowitz et al.
. 58.	01/30/2004	10/769,046	Rabinowitz et al.
59.	01/30/2004	10/769,051	Rabinowitz et al.
60.	01/29/2004	10/769,157	Rabinowitz et al.
61.	01/29/2004	10/769,197	Rabinowitz et al.
62.	02/09/2004	10/775,583	Rabinowitz et al.
63.	02/09/2004	10/775,586	Rabinowitz et al.
64.	03/03/2004	10/791,915	Hale et al.
65.	03/03/2004	10/792,012	Hale et al.
66.	03/03/2004	10/792,013	Rabinowitz et al.
67.	03/03/2004	10/792,096	Hale et al.
68.	03/03/2004	10/792,239	Hale et al.
69.	03/31/2004	10/813,721	Rabinowitz et al.
70.	03/31/2004	10/813,722	Rabinowitz et al.
71.	03/31/2004	10/814,690	Rabinowitz et al.
72.	03/31/2004	10/814,998	Rabinowitz et al.
73.	04/01/2004	10/815,527	Rabinowitz et al.
74.	04/01/2004	10/816,407	Rabinowitz et al.
75.	04/01/2004	10/816,492	Rabinowitz et al.
76.	04/01/2004	10/816,567	Rabinowitz et al.
77.	08/04/2004	10/912,462	Hale et al.
78.	01/23/2003	US 2003/0015196	Hodges et al.
79.	04/03/2003	US 2003/0062042	Wensley et al.
80.	11/13/2003	US 2003/0209240	Hale et al.
81.	01/02/2003	US 2003/0000518	Rabinowitz et al.
82.	01/09/2003	US 2003/0005924	Rabinowitz et al.
83.	01/09/2003	US 2003/0005925	Hale et al.
EXAMINER:			DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449		Docket Number: 00010.05CON	Application Number: 10/792,001	
		Application of all		
	INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Rabinowitz et al.	
	(Use several sheets if nec	essary)	Filing Date: 03/03/2004	Group Art Unit: Not Yet Known
84.	01/09/2003	US 2003/0007933	Rabinowitz et al.	
85.	01/09/2003	US 2003/0007934	Rabinowitz et al.	
86.	01/16/2003	US 2003/0012737	Rabinowitz et al.	1
87.	01/16/2003	US 2003/0012738	Rabinowitz et al.	
88.	1/16/2003	US 2003/0012740	Rabinowitz et al.	
89.	01/23/2003	US 2003/0015189	Rabinowitz et al.	
90.	01/23/2003	US 2003/0015190	Rabinowitz et al.	
91.	01/23/2003	US 2003/0017114	Rabinowitz et al.	
92.	01/23/2003	US 2003/0017115	Rabinowitz et al.	
93.	01/23/2003	US 2003/0017116	Rabinowitz et al.	
94.	01/23/2003	US 2003/0017117	Rabinowitz et al.	
95.	01/23/2003	US 2003/0017118	Rabinowitz et al.	
96.	01/23/2003	US 2003/0017119	Rabinowitz et al.	
97.	01/23/2003	US 2003/0017120	Rabinowitz et al.	
98.	1/30/2003	US 2003/0021753	Rabinowitz et al.	
99.	01/30/2003	US 2003/0021754	Rabinowitz et al.	
100.	01/30/2003	US 2003/0021755	Hale et al.	
101.	02/20/2003	ÚS 2003/0035776	Hodges et al.	
102.	05/15/2003	US 2003/0091511	Rabinowitz et al.	
103.	05/27/2004	US 2004/010148	Hale et al.	
104.	07/31/2003	US 2003/0138382	Rabinowitz	
105.	11/06/2003	US 2003/0206869	Rabinowitz et al.	
106.	01/15/2004	US 2004/0009128	Rabinowitz et al.	
107.	05/20/2004	US 2004/0096402	Hodges et al.	
108.	05/27/2004	US 2004/0099269	Hale et al.	
109.	06/03/2004	US 2004/0105818	Hale et al.	
110.	06/03/2004	US 2004/0105819	Hale et al.	
111.	07/01/2004	US 2004/0126326	Rabinowitz et al.	
112.	07/01/2004	US 2004/0126327	Rabinowitz et al.	
113.	07/01/2004	US 2004/0126328	Rabinowitz et al.	
EXAMINER:			DATE CONSIDÈRED:	
EYAMINED. 1-	nitial if aitation annother	rad whather or not the sit-t	ion conforms with MPEP 609 Draw a	ling through the situation if not in

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTC	)-1449			Docket Number: 00010.05CON A		Application Number: 10/792,001	
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicant: Rabinow	itz et al.				
	(L	Ise several sheets if nec	ressary)	Filing Date: 03/03/200	04	Group Art Unit:	Not Yet Known
			*				
	114.	07/01/2004	US 2004/0126329	Rabinowitz et al.			
	115.	07/01/2004	US 2004/0127481	Rabinowitz et al.			
	116.	07/01/2004	US 2004/0127490	Rabinowitz et al.			
	117.	08/12/2004	US 2004/0156788	Rabinowitz et al.			
	118.	08/12/2004	US 2004/0156789	Rabinowitz et al.			
	119.	8/12/2004	US 2004/0156790	Rabinowitz et al.			
FOREIGN PATENT DOCUMENTS							
Examiner Initials	Ref.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	120.	01/02/1996	CA 2,152,684	Canada			
	121.	03/14/1990	EP 0 358 114	Europe			
	122.	03/07/2001	EP 1 080 720	Europe			•
	123.	08/29/2001	EP 0 606 486	Europe			
	124.	04/11/1996	WO 96/09846	WIPO			
	125.	05/09/1996	WO 96/13161	WIPO			
	126.	05/09/1996	WO 96/13290	WIPO			
	127.	05/09/1996	WO 96/13291	WIPO			
	128.	05/09/1996	WO 96/13292	WIPO			
	129.	10/03/1996	WO 96/30068	WIPO			
	130.	08/07/1997	WO 97/27804	WIPO		4	
	131.	05/28/1998	WO 98/22170	WIPO			
	132.	07/23/1998	WO 98/31346	WIPO			
	133.	08/27/1998	WO 98/36651	WIPO			
	134.	04/08/1999	WO 99/16419	WIPO			•
	135.	12/16/1999	WO 99/64094	WIPO			
	136.	01/06/2000	WO 00/00176	WIPO			
	137.	01/06/2000	WO 00/00215	WIPO			
EXAMINER:			DATE CONSIDER	ED:			

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

E DTO 1440		Docket Number:	00010.05CON	Application Nu	mber: 10/792,001	
Form PTO-1449		DOCACTIVATIBLES. OUTIO.OCOM				
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)		Applicant:	Rabinowitz et a			
		Filing Date:	03/03/2004	Group Art Unit	Not Yet Known	
				<u></u>		
138.	05/18/2000	WO 00/27363	WIPO			
139.	05/25/2000	WO 00/29053	WIPO			
140.	09/17/2000	WO 00/47203	WIPO			
141.	11/02/2000	WO 00/64940	WIPO		·	
142.	11/09/2000	WO 00/66084	WIPO			
143.	11/09/2000	WO 00/66206	WIPO			
144.	12/07/2000	WO 00/72827	WIPO			
145.	12/21/2000	WO 00/76673	WIPO			
146.	01/25/2001	WO 01/05459	WIPO			
147.	03/28/2002	WO 02/24158	WIPO			

DATE CONSIDERED: EXAMINER:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

					Sheet / of 8		
Form PTO-1449			Docket Number	: 00010.05CON	Application Number: 10/792,001		
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			Applicant:	Rabinowitz et al.			
	(L	lse several sheets if necessary)	Filing Date:	03/03/2004	Group Art Unit: Not Yet Known		
		OTHER DOCUMENTS	(including	author, title, Date, Pertin	nent Pages, Etc.)		
Examiner Initials	Ref. No.	Title					
	148.	Bennett, R.L. et al. (1981). "Patient-C Relief," Annual Surg. 195(6):700-705		algesia: A New Cor	ncept of Postoperative Pain		
	149. Carroll, M.E. et al. (1990), "Cocaine-base smoking in rhesus monkeys: reinforcing and physiologeffects," <i>Psychopharmacology</i> (Berl). 102:443-450.						
	150.	Clark, A. and Byron, P. (1986). "Dependence of Pulmonary Absorption Kinetics on Aerosol Particle Size," Z. Erkrank. 166:13-24.					
	151.	Darquenne, C. et al. (1997). "Aerosol Simulations and Experiments for Bolu					
	152.	Davies, C.N. et al. (May 1972). "Breathing of Half-Micron Aerosols," Journal of Applied Physiology. 32(5):591-600.					
	153.	Dershwitz, M., M.D., et al. (Septembe versus Intravenous Morphine in Healt					
	154.	Finlay, W.H. (2001). "The Mechanics Diego Formula 2.39. pp.3-14 (Table of			osols", Academic Press: San		
	155.	Gonda, I. (1991). "Particle Deposition Scientific Foundations. Crystal R.G. a 2294.					
	156.	Hatsukami D, et al. (May 1990) "A m humans." Pharmacology Biochemistry	ethod for deli	very of precise dos . 36(1):1-7.	ses of smoked cocaine-base to		
	157.	Heyder, J. et al. (1986). "Deposition of 0.005-15 μm," J. Aerosol Sci. 17(5):8		the Human Respira	atory Tract in the Size Range		
	158.	Huizer, H., "Analytical studies on illic Pharmaceutisch Weekblad Scientific			ration during heroin smoking."		
	159.	Hurt, R.D., MD and Robertson, C.R., Industry's Secrets About Nicotine: Th					
	160.	Lichtman, A.H. et al. (1996). "Inhalat in Mice," Journal of Pharmacology and					
	161.	Martin, B.R. and Lue, L.P. (May/June Analytical Toxicology 13:158-162.	1989). "Pyro	lysis and Volatiliz	ation of Cocaine," Journal of		
			DATE	CONGINEDED			
EXAMII	NER:	·	DATE	CONSIDERED:			
EXAMIN	ER: Init	ial if citation considered, whether or not the citat	ion conforms wi	th MPEP 609. Draw a	line through the citation if not in		

conformance and not considered. Include a copy of this form with next communication to applicant.

PTO/SB/08 (2-92) Sheet 8 of 8

Form PTO-1449	Docket Number: 00010.05CON Application Number: 10/792					
	ION DISCLOSURE CITATION AN APPLICATION	Applicant:	Rabinowitz et al.			
	lse several sheets if necessary)	Filing Date:	03/03/2004	Group Art Unit: Not Yet Known		
162.	Mattox, A.J. and Carroll, M.E., (1996) Psychopharmacology, 125:195-201.			·		
163. Meng, Y. et al. "Inhalation Studies With Drugs of Abuse, " NIDA Research Monograph, (1997) 173:201-224.						
164.	Meng, Y., et al. (1999). "Pharmacolog inhalation exposure," Drug and Alcoh	gical effects of ol Dependence	methamphetamir e. 53:111-120.	ne and other stimulants via		
165.	Office Action mailed 8/13/2003 for US application 10/153,313 filed 05/21/2002 "DELIVERY CBENZODIAZEPINES THROUGH AN INHALATION ROUTE".					
166.	Pankow, J.F. et al. (1997). "Conversion of Nicotine in Tobacco Smoke to Its Volatile and Available Free-Base Form Through the Action of Gaseous Ammonia," <i>Envron. Sci. Technol.</i> 31:2428-2433.					
167.	Pankow, J. (March 2000). ACS Conference-San Francisco-3/26/00. Chemistry of Tobacco Smoke.					
168.	Seeman, J. et al. (1999). "The Form of Nicotine in Tobacco. Thermal Transfer of Nicotine and Nicotine Acid Salts to Nicotine in the Gas Phase," J. Agric. Food Chem. 47(12):5133-5145.					
169.	Sekine, H. and Nakahara, Y. (1987). "Inhalation Efficiency and Pyrolysis Pr 32(5):1271-1280.	'Abuse of Smoroducts of Me	oking Methamphe thamphetamine,"	tamine Mixed with Tobacco: 1.  Journal of Forensic Science		
170.	Vapotronics, Inc. (1998) located at htt June 5, 2000).	p://www.vapo	otronics.com.au/b	anner.htm., 11 pages, (visited on		
171.	Ward, M.E. MD, et al. (December199 Administration from a Novel Aerosol 62(6):596-609.	77). "Morphine Delivery Sys	e Pharmacokinetic tem," Clinical Pho	cs after Pulmonary armacology & Therapeutics		
172.	Wood, R.W. et al. (1996). "Generation Pyrolyzate, Methylecgonidine, and De Biochemistry & Behavior. 55(2):237-2	emonstration.	st Atmospheres o of Their Biologica	f Cocaine Base and Its al Activity." Pharmacology		
·			•			
			· ·			
EXAMINER:		DATE	CONSIDERED:			
	tial if citation considered, whether or not the citat	ion conforms wi	th MPEP 609. Draw	a line through the citation if not in		

conformance and not considered. Include a copy of this form with next communication to applicant.